Deja vu all over again? There is chatter on YMB th

Message Board

Previous

| Next

Post# of 148264

(Total Views: 699)

Posted On: 12/21/2020 8:52:17 PM

Posted By: blafarm

Re: mtruong34 #69108

Quote:
Deja vu all over again? There is chatter on YMB that the LH WSJ article has been revised to focus less on LL & Cytodyn. Anyone with an account with WSJ can confirm or deny?

I can confirm this.

Here is the relevant CytoDyn excerpt from this afternoon's version:

Quote:
CytoDyn, a Vancouver, Wash., biotechnology company, recently applied to the U.S. Food and Drug Administration to test its experimental drug, leronlimab, on 102 long Covid patients, says Scott A. Kelly, chief medical officer of the company.

Leronlimab, a monoclonal antibody administered through subcutaneous injections, was developed as an HIV drug. When the pandemic hit, the company shifted to Covid-19. The same receptor that allows HIV to enter cells is also important in regulating immune cells; some doctors believe long-term Covid symptoms are caused by the immune system going haywire. The company has recently tested the treatment in severe Covid patients as well as in mild to moderate cases, some of which were long-haul patients.

Some patients with long-term symptoms reported their brain fog and cognition issues improving after treatment. “When we started to see these patients saying the brain fog was clearing, we were encouraged,” says Dr. Kelly. A new trial would test the drug specifically on long-haul patients.

Dr. Kelly says they believe leronlimab may be alleviating brain inflammation. Leronlimab binds to a cell receptor that contributes to the regulation of immune cells that sometimes flood an area and destroy tissue. Blocking that receptor may slow down the inflammatory response, which some scientists believe is triggering problems in long Covid patients.

“We are hopeful we can control the neuroinflammation in the brain which we think causes a lot of these problems with autonomic dysfunction, fatigue, brain fog,” says Dr. Kelly. The company says patients haven’t reported significant side effects in the clinical trials they’ve done for Covid and HIV.

Dr. Kelly says the interest in such a treatment is tremendous. “I get emails every day about wanting to participate in the trial,” he says.

And here is the relevant CytoDyn excerpt from this evening's version:

Quote:
Before Covid-19, Mr. Varnes was a fitness buff. He went to a CrossFit gym five days a week. Now, he can’t do much more than go on a walk. “I’ve had shortness of breath every single day,” says Mr. Varnes.

He heard about a drug called leronlimab from an online support group and reached out to a physician who runs clinical trials for CytoDyn, a Vancouver, Wash., biotechnology company. It recently applied to the U.S. Food and Drug Administration to test its experimental drug, leronlimab, on 102 long Covid patients, says Scott A. Kelly, chief medical officer of the company.

Leronlimab, a monoclonal antibody administered through subcutaneous injections, was developed as an HIV drug. It hasn’t been FDA approved for HIV or for Covid. The company has recently tested the treatment in severe Covid patients as well as in mild to moderate cases, some of which were long-haul patients. The research is preliminary; there is no published data from human trials validating the results. A new trial would test the drug specifically on long-haul patients. The company says patients haven’t reported significant side effects in the clinical trials they’ve done for Covid and HIV.